TABLE 4.
Prevalence of Post‐COVID GI symptoms in an anonymous survey of survivors.
| All respondents (n = 285) | No post‐COVID GI symptoms (n = 172) | Post‐COVID GI symptoms* (n = 113) | p‐value | |
|---|---|---|---|---|
| Age | ||||
| 18–29 | 48 (17%) | 35 (73%) | 13 (27%) | 0.31 |
| 30–39 | 67 (24%) | 41 (61%) | 26 (39%) | |
| 40–49 | 49 (17%) | 26 (53%) | 23 (47%) | |
| 50–59 | 58 (21%) | 31 (53%) | 27 (47%) | |
| 60–69 | 47 (17%) | 29 (62%) | 18 (38%) | |
| ≥70 | 12 (4.3%) | 6 (50%) | 6 (50%) | |
| Sex | ||||
| Female | 198 (71%) | 114 (58%) | 84 (42%) | 0.25 |
| Male | 80 (29%) | 52 (65%) | 28 (35%) | |
| Race | ||||
| White | 242 (86%) | 141 (58%) | 101 (42%) | 0.36 |
| Black | 9 (3.2%) | 7 (78%) | 2 (22%) | |
| Asian | 10 (3.6%) | 8 (80%) | 2 (20%) | |
| Other | 21 (7.5%) | 13 (62%) | 8 (38%) | |
| Ethnicity | ||||
| Hispanic | 25 (9.4%) | 14 (56%) | 11 (44%) | 0.73 |
| Non‐Hispanic | 240 (91%) | 143 (60%) | 97 (40%) | |
| Depression | ||||
| No | 202 (71%) | 125 (62%) | 77 (38%) | 0.41 |
| Yes | 83 (29%) | 47 (57%) | 36 (43%) | |
| Anxiety | ||||
| No | 192 (67%) | 118 (61%) | 74 (39%) | 0.58 |
| Yes | 93 (33%) | 54 (58%) | 39 (42%) | |
| Fibromyalgia | ||||
| No | 272 (95%) | 166 (61%) | 106 (39%) | 0.28 |
| Yes | 13 (4.6%) | 6 (46%) | 7 (54%) | |
| Diagnosis Type | ||||
| PCR | 192 (67%) | 111 (58%) | 81 (42%) | 0.57 |
| Antibody | 21 (7.4%) | 15 (71%) | 6 (29%) | |
| Symptoms | 63 (22%) | 40 (63%) | 23 (37%) | |
| Unsure | 9 (3.2%) | 6 (67%) | 3 (33%) | |
| GI symptoms at diagnosis | ||||
| No | 85 (30%) | 62 (73%) | 23 (27%) | 0.01 |
| Yes | 200 (70%) | 110 (55%) | 90 (45%) | |
| Hospitalized | ||||
| No | 249 (88%) | 150 (60%) | 99 (40%) | 0.87 |
| Yes | 34 (12%) | 20 (59%) | 14 (41%) | |
| Intubated | ||||
| No | 279 (98%) | 169 (61%) | 110 (39%) | 0.60 |
| Yes | 6 (2.1%) | 3 (50%) | 3 (50%) | |
| Received Antibiotics | ||||
| No | 206 (72%) | 133 (65%) | 73 (35%) | 0.02 |
| Yes | 79 (28%) | 39 (49%) | 40 (51%) | |
| Received Hydroxychloroquine | ||||
| No | 272 (95%) | 168 (62%) | 104 (38%) | 0.03 |
| Yes | 13 (4.6%) | 4 (31%) | 9 (69%) | |
| Received Steroids | ||||
| No | 233 (82%) | 141 (61%) | 92 (39%) | 0.91 |
| Yes | 52 (18%) | 31 (60%) | 21 (40%) | |
| Time from diagnosis | ||||
| < 1 month | 91 (32%) | 64 (70%) | 27 (30%) | 0.01 |
| 1–3 months | 38 (13%) | 15 (39%) | 23 (61%) | |
| 3–6 months | 44 (15%) | 25 (57%) | 19 (43%) | |
| >6 months | 112 (39%) | 68 (61%) | 44 (39%) | |
*
Presence of at least weekly abdominal pain, associated with altered bowel habits, among all respondents without pre‐existing IBS. Patients with any follow‐up length of time were included in this analysis.